Silexion Therapeutics Announces $2.5M Public Offering and Debt Conversion

What Happened
Silexion Therapeutics (SLXN) announced a registered public offering that priced on August 11, 2026 and closed on August 13, 2026, raising approximately $2.5 million in gross proceeds (before any future warrant exercises). The offering sold 2,028,619 ordinary shares, 1,817,542 pre‑funded warrants and 3,846,161 Series E ordinary warrants. Concurrently, the company converted $750,001 of a promissory “Sponsor Note” into 1,153,848 ordinary shares at $0.65 per share and recorded prior exercises of pre‑funded warrants totaling 823,770 shares. The company said net proceeds (before offering expenses) were about $2.1 million and that it will use the funds to advance the SIL204 clinical trial and for general corporate purposes.

Key Details

• Offering size and pricing: ~2.5M gross proceeds; public price $0.65 per share + ordinary warrant; pre‑funded warrants sold at $0.6499 each.
• Warrant economics: Pre‑funded warrants exercisable immediately at $0.0001 (no expiration); Ordinary Warrants exercisable at $0.65 for 5 years; placement agent warrants (269,231) exercisable at $0.8125 for 5 years.
• Placement agent and fees: H.C. Wainwright acted as placement agent; company paid a 7.0% cash fee + 1.0% management fee, reimbursed up to $70,000 in counsel/out‑of‑pocket expenses, and issued placement agent warrants.
• Balance sheet impact: $750,001 of sponsor debt converted into 1,153,848 shares (remaining note balance $206,462); after recent ATM sales, offering, conversion and warrant exercises, estimated shareholders' equity as of June 30, 2026 is approximately $3.2M (preliminary, unaudited).

Why It Matters
This 8‑K shows Silexion raised fresh capital and reduced a portion of sponsor debt, providing short‑term funding for its SIL204 clinical program and general operations. Investors should note dilution from the new shares and multiple classes of warrants (and the placement agent warrants), as well as the ownership caps on warrant exercises (4.99% default, up to 9.99% by election). The proceeds improve near‑term liquidity but do not eliminate the company’s need for further financing; the company’s reported shareholders’ equity figure is preliminary and unaudited.